Andreas Meyerhans is an expert in Immunology at Pompeu Fabra University (Spain). Andreas Meyerhans has authored 179 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 584 (community average: 125). How the SLR is computed.

LeadR Profile

Andreas Meyerhans Pompeu Fabra University Spain
584 ScienceLeadR Reputation 584
Network Map

Immunology

Subspecialties: Infectiology - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026

Source: PubMed

Institució Catalana de Recerca i Estudis Avançats

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 179

Citations

Citations: 6 572 1st author: 2 Last author: 73 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial.
PMID 42498486 — cells, lung, monocytes, vaccines, neoplasms, drug therapy, maintenance, immunotherapy, vaccination, lung neoplasms, small cell lung carcinoma, therapeutics, dendritic cells, chemotherapy
J Immunother Cancer20261
Dynamics and Sensitivity of the Lifecycle of Hepatitis B Virus.
PMID 41754425 — cells, hepatitis b virus, virion, nucleosides, herpesvirus 1, cercopithecine, capsid, viruses, hepatitis b, antiviral agents, infections, hepatitis
Pathogens20260
Challenges in the Vaccination of HIV-Infected Individuals.
PMID 41600956 — vaccines, vaccination, hiv, therapeutics, immunosuppression therapy
Vaccines (Basel)20250
Quantifying the Inhibitory Efficacy of HIV-1 Therapeutic Interfering Particles at a Single CD4 T-Cell Resolution.
PMID 41157648 — cells, hiv-1, virion, antiretroviral therapy, highly active, hiv, viruses, interferon type i, defective viruses, therapeutics, t-lymphocytes, infections
Viruses20250
Lessons from the European mpox outbreak: strengthening cohort research for future pandemic preparedness.
PMID 40854466 — disease outbreaks, vaccines, data collection, cohort studies, microbiology, parasitic diseases, research, pandemics, therapeutics, communicable diseases, infections
Clin Microbiol Infect20250

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 1 1
Phase 1/Phase 2 1
Phase 2 1

By status:

Completed 2
Terminated 1

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 1
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map